NNVC NanoViricides Inc
Company Analysis
Latest News
🔴 NanoViricides is trading 6% down
NanoViricides is trading 6.00% lower at $1.41, with no clear company-specific announcement explaining the September 29 decline. - The company announced on...
🟢 NanoViricides is trading 6% up in pre-market after Phase II NV-387 Ebola trial dosing began
NanoViricides is trading 6.02% higher in pre-market at $1.59 after enrollment and dosing began in its Phase II oral NV-387 Ebola trial. - It closed at $1.50 on...
🟢 NanoViricides is trading 5% up today after Phase II Ebola trial dosing began
NanoViricides is trading 5.21% higher at $1.51 after announcing that enrollment and dosing began in its Phase II oral NV-387 Ebola trial. - The company...
🔴 NanoViricides is trading 5.4% down today amid biotech-sector weakness
NanoViricides is trading at $1.43 (-5.40%) as biotechnology-sector weakness weighs on shares. - NanoViricides is declining despite September 23 news that...
🟢 NanoViricides is trading 6.54% up today after Phase II MPox trial enrollment began
NanoViricides is trading 6.54% up at $1.63; on September 23, 2026, it announced that enrollment of the first patients began in its Phase II NV-387 trial for...
🟢 NanoViricides is trading 8.52% up in pre-market
NanoViricides is trading 8.52% higher at $1.66 in pre-market, rebounding from its September 22 close of $1.53; no immediate catalyst has been identified. - No...
🟢 NanoViricides is trading 6.19% up in after-hours trading; catalyst unclear
NanoViricides is trading 6.19% higher at $1.63 after rising following a 9.17% regular-session decline on September 22, 2026; the cause remains unclear. - No...
🔴 NanoViricides is trading 6.51% down today
NanoViricides is trading 6.51% lower at $1.58, with no clearly reported company-specific negative catalyst identified for September 22, 2026. - The latest...
🟢 NanoViricides is trading 13.79% up today on Phase II Ebola trial interest
NanoViricides is trading 13.79% up at $1.62 as investor interest builds around its Phase II NV-387 oral-gummy Ebola trial. - The study is scheduled to begin...
🟢 NanoViricides is trading 6.33% up today on investor interest in Phase II Ebola trial
NanoViricides is trading 6.33% up at $1.56 as investor interest continues around its Phase II NV-387 oral-gummy Ebola trial. - The trial is scheduled to begin...
🟢 NanoViricides is trading 7% up in pre-market ahead of Phase II Ebola trial start
NanoViricides is trading at $1.52, up 7.04% now, extending gains after its September 15 announcement that the Phase II NV-387 oral-gummy Ebola trial is...
🟢 NanoViricides is trading 5% up today ahead of Phase II Ebola trial start
NanoViricides is trading 5% up at $1.47 after investors continued reacting to the company’s September 15 announcement that its Phase II NV-387 oral-gummy Ebola...
🟢 NanoViricides Inc is trading 5.00% up in pre-market
NNVC is trading at $1.47, up 5.00% in pre-market.
🟢 NanoViricides is trading 5.6% up in after-hours trading ahead of Phase II Ebola trial next week
NanoViricides is trading 5.6% up at $1.50 after announcing that its Phase II NV-387 oral-gummy Ebola trial is scheduled to begin next week in Ituri province,...
🟢 NanoViricides is trading 15.01% up today ahead of Phase II NV-387 Ebola trial next week
NanoViricides is trading 15.01% up now at $1.37 after announcing that its Phase II NV-387 oral-gummy Ebola trial is scheduled to begin next week. - The trial...
🟢 NanoViricides is trading 11.67% up today ahead of Phase II Ebola trial
NanoViricides is trading at $1.34, up +11.67%, as investors react to the upcoming clinical milestone. - Shares are extending the prior session’s 14.29%...
🟢 NanoViricides is trading 9.17% up today as first-patient dosing is expected next week
NanoViricides is trading 9.17% up now at $1.30 after announcing first-patient dosing for its Phase II NV-387 oral-gummy Ebola trial is expected next week in...
🟢 NanoViricides is trading 10.46% up in pre-market after Phase II Ebola trial dosing scheduled next week
NanoViricides is trading $1.33 (+10.46%) after announcing Phase II NV-387 oral-gummy Ebola trial dosing is scheduled next week in the Democratic Republic of...
🟢 NanoViricides is trading 5% up in pre-market after Phase II Ebola trial dosing announcement
NanoViricides is trading 5% up now at $1.26 after investors responded positively to the September 15 announcement that its Phase II NV-387 oral-gummy Ebola...
🟢 NanoViricides is trading 5.35% up in after-hours trading on optimism over upcoming oral Ebola trial
NanoViricides is trading 5.35% up at $1.28 after-hours on optimism following the September 15 announcement that its Phase II NV-387 oral-gummy Ebola trial in...